by David Ponting, Senior Principal Scientist, Lhasa Limited On 24 September 2026, the US Food and Drug Administration (FDA) published a guidance …
Forced degradation study design that is both defensible and efficient requires insight into the specific reactivity of an API before work begins …
As governments and regulators across the UK, EU and beyond move to reduce reliance on animal testing, the need for reliable and …
Nitrosamine qualification remains one of the most complex and fast-moving areas in pharmaceutical safety assessment. As scientific understanding advances and regulatory expectations …
Join us for a recap of the Lhasa Pharmaceutical Science Symposiums held in Colombia and Argentina in March 2026. Participants gained a …
At Lhasa, we believe that the future of science is built on collaboration and the brilliance of the next generation. We are …